Physician profile
Clark Dreilinger
NPI 1225026743
$4,850.44
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $248 · 2021: $424 · 2022: $1,581 · 2023: $1,642 · 2024: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.19 | 2021-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $724.92 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $558.85 | 2019-2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $550.42 | 2019-2024 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $530.78 | 2019-2024 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $453.66 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $432.69 | 2021-2024 | Caplyta |
| Lundbeck LLC | $260.52 | 2020-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $250.19 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.89 | 2019 | |
| Indivior INC. | $46.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.55 | 2021-2023 | Trintellix |
| Biogen, INC. | $28.07 | 2024 | |
| Almatica Pharma LLC | $21.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Dreilinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.